Insulet Corporation (PODD)

NMS – Цена в реальном времени. Валюта: USD

158.25

+4.43 (2.88%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

158.99

+0.74 (0.47%)

После закрытия: Jun 26, 2026, 7:31 PM EDT

12.06.2026

Insulet Corporation (PODD) Discusses Recent Product Recalls and Physician Community Response at ADA Meeting Transcript

11.06.2026

Why Insulet (PODD) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

08.06.2026

Insulet Corporation Valuation Pressure Has Dropped Enough (Upgrade)

Insulet Corporation has rebounded with strong revenue and profit growth, now approaching the lower end of fair value. PODD delivered Q1 2026 revenue of $761.7M (+33.9% YoY), with net income and operating cash flow nearly doubling. Management forecasts 21–23% revenue growth in 2026, driven by Omnipod 5 adoption and international expansion, despite competitive threats from weight-loss drugs.

06.06.2026

Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care

ACTON, Mass.--(BUSINESS WIRE)--Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort.

05.06.2026

Why Is Insulet (PODD) Down 8.7% Since Last Earnings Report?

Insulet (PODD) reported earnings 30 days ago. What's next for the stock?

04.06.2026

Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessions

ACTON, Mass.--(BUSINESS WIRE)--Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at ADA.

03.06.2026

Insulet Corporation (PODD) Presents at 46th Annual William Blair Growth Stock Conference Transcript

Видео

04.11.2025

Neutral

Final Trades: Insulet Corp, Uber and Apollo Global

Пресс-релизы

06.06.2026

Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care

ACTON, Mass.--(BUSINESS WIRE)--Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort.

04.06.2026

Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessions

ACTON, Mass.--(BUSINESS WIRE)--Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at ADA.

03.06.2026

Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor

ACTON, Mass.--(BUSINESS WIRE)--Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor.

27.05.2026

Insulet to Participate in William Blair 46th Annual Growth Stock Conference

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the William Blair 46th Annual Growth Stock Conference in Chicago on Wednesday, June 3, 2026 at 2:00 p.m. (Central Time). The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About Insulet Corporation: Insul.

Insulet Corporation (PODD)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Insulet Corporation (PODD)

Insulet Corporation (PODD) Discusses Recent Product Recalls and Physician Community Response at ADA Meeting Transcript

Why Insulet (PODD) is a Top Momentum Stock for the Long-Term

Insulet Corporation Valuation Pressure Has Dropped Enough (Upgrade)

Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care

Why Is Insulet (PODD) Down 8.7% Since Last Earnings Report?

Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessions

Insulet Corporation (PODD) Presents at 46th Annual William Blair Growth Stock Conference Transcript

Видео

Пресс-релизы

Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care

Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessions

Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor

Insulet to Participate in William Blair 46th Annual Growth Stock Conference

Insulet Corporation (PODD) Discusses Recent Product Recalls and Physician Community Response at ADA Meeting Transcript

Why Insulet (PODD) is a Top Momentum Stock for the Long-Term

Insulet Corporation Valuation Pressure Has Dropped Enough (Upgrade)

Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care

Why Is Insulet (PODD) Down 8.7% Since Last Earnings Report?

Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessions

Insulet Corporation (PODD) Presents at 46th Annual William Blair Growth Stock Conference Transcript

Видео

Пресс-релизы

Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care

Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessions

Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor

Insulet to Participate in William Blair 46th Annual Growth Stock Conference

Search stocks

Insulet Corporation (PODD)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Insulet Corporation (PODD)

Insulet Corporation (PODD) Discusses Recent Product Recalls and Physician Community Response at ADA Meeting Transcript

Why Insulet (PODD) is a Top Momentum Stock for the Long-Term

Insulet Corporation Valuation Pressure Has Dropped Enough (Upgrade)

Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care

Why Is Insulet (PODD) Down 8.7% Since Last Earnings Report?

Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessions

Insulet Corporation (PODD) Presents at 46th Annual William Blair Growth Stock Conference Transcript

Видео

Пресс-релизы

Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care

Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessions

Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor

Insulet to Participate in William Blair 46th Annual Growth Stock Conference

Insulet Corporation (PODD) Discusses Recent Product Recalls and Physician Community Response at ADA Meeting Transcript

Why Insulet (PODD) is a Top Momentum Stock for the Long-Term

Insulet Corporation Valuation Pressure Has Dropped Enough (Upgrade)

Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care

Why Is Insulet (PODD) Down 8.7% Since Last Earnings Report?

Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessions

Insulet Corporation (PODD) Presents at 46th Annual William Blair Growth Stock Conference Transcript

Видео

Пресс-релизы

Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care

Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessions

Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor

Insulet to Participate in William Blair 46th Annual Growth Stock Conference